Analysts expect Madrigal Pharmaceuticals, Inc. to report revenue of 383.08 M for Q3 26, against a range of 360.65 M to 405.51 M. The most recent reported quarter, Q2 26, came in at 364.30 M, a 6.6% beat against the 341.84 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 62.20 M | 103.32 M | 137.25 M | 212.80 M | 287.27 M | 321.10 M | 311.34 M | 364.30 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 35.17 M | 109.38 M | 122.53 M | 178.47 M | 289.97 M | 329.26 M | 330.43 M | 369.59 M | 405.51 M | 455.23 M | 459.52 M | 530.44 M | 636.32 M | 659.32 M | 680.35 M | 680.18 M | ||||||||||
| Low Estimate | 29.63 M | 102.11 M | 113.73 M | 152.15 M | 239.29 M | 280.25 M | 286.88 M | 314.09 M | 360.65 M | 413.39 M | 391.12 M | 442.49 M | 565.25 M | 581.85 M | 621.87 M | 622.64 M | ||||||||||
| Consensus Estimate | 32.40 M | 105.75 M | 118.13 M | 165.31 M | 264.63 M | 304.76 M | 308.65 M | 341.84 M | 383.08 M | 434.31 M | 425.32 M | 486.47 M | 600.78 M | 620.59 M | 651.11 M | 651.41 M |
Analysts expect Madrigal Pharmaceuticals, Inc. to report earnings per share of -0.87 for Q3 26, against a range of -0.93 to -0.81. The most recent reported quarter, Q2 26, came in at -1.99, a 20.7% beat against the -2.51 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -4.92 | -2.71 | -3.32 | -1.90 | -5.08 | -2.57 | -3.25 | -1.99 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -6.35 | -3.85 | -3.74 | -3.20 | -2.32 | -0.87 | -4.19 | -2.26 | -0.81 | -0.11 | -0.31 | 0.96 | 1.14 | 2.68 | 4.45 | 6.14 | ||||||||||
| Low Estimate | -7.69 | -4.35 | -4.00 | -3.54 | -2.52 | -0.97 | -4.45 | -2.76 | -0.93 | -0.13 | -0.35 | 0.82 | 1.00 | 2.28 | 3.87 | 5.34 | ||||||||||
| Consensus Estimate | -7.02 | -4.10 | -3.87 | -3.37 | -2.42 | -0.92 | -4.32 | -2.51 | -0.87 | -0.12 | -0.33 | 0.89 | 1.07 | 2.48 | 4.16 | 5.74 |
Pull Wall Street consensus for Madrigal Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=MDGL&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "MDGL", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=MDGL&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();